iRhythm Technologies, Inc. (IRTC)
Valor JustoFundamental
43
Preço
$111.79
Capitalização de Mercado
$3.75B
Parte 1 · Quanto vale a empresa
Visão Geral
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.
Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.
GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.
Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.
Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.
This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.
Balanço & Liquidez
Receita
$825M
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-14M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$35M
Capital Próprio Total
$153M
Passivo Total
$867M
Rácio de Liquidez
3.85
Cobertura de Juros
1.89
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$104.37
Preço Atual
$111.79
Margem de Segurança
-7.1%
Intervalo de Valor Justo
$67.84 - $140.89
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-29.2%
Rácio P/B
20.14
P/FCF
96.12
Margem Bruta
71.5%
ROIC
-2.2%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
-2.2%
WACC
10.5%
ROIC − WACC
-12.7 pp
O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.
Critérios de Análise Fundamental
Aprovado (12)
- EPS shows upward trend
- Price CAGR 14.06%
- Gross Margin 71.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 23.0%
- Analyst Consensus 95% Buy
- Earnings Surprise avg 3463.2%
- Net Margin Trend -1.7% vs -14.1%
- Piotroski F-Score 6/9
Reprovado (10)
- ROIC -2.2%
- P/FCF 96.12
- P/B Ratio 20.14
- Debt/Equity ratio
- Operating Margin -3.0%
- CapEx intensity
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -9.0%
- Share Dilution 2.7%
Indisponível (5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A emitir novas ações, diluindo a participação
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Quentin S. Blackford | President, CEO & Director | 46 |
| Mr. Daniel G. Wilson | CFO & Principal Financial Officer | 43 |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Advanced Technologies | 51 |
| Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 46 |
| Mr. Chad M. Patterson | Chief Commercial and Product Officer | 43 |
| Mr. Mervin Smith | Executive Vice President of Business Operations | 50 |
| Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Brian Lawrence | Executive VP & CTO | 55 |
| Ms. Lisa Pecora | Senior Vice President of Finance & Investor Relations | - |
| Mr. Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | 49 |
Risco de Auditoria
9
Risco do Conselho
5
Risco de Remuneração
3
Risco dos Direitos dos Acionistas
7
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-19
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-06
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-09-22
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for IRTC, sourced from Markets Gazette.
- 3d agoPOSITIVEJP Morgan forecasts a 20x revenue increase for this AI stock
JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.
- 6/16/2026NEGATIVEiRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data
iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.
via Markets Gazette